Status:
ACTIVE_NOT_RECRUITING
Hydroxychloroquine May be Beneficial for Preeclampsia
Lead Sponsor:
RenJi Hospital
Conditions:
Pre-Eclampsia
Eligibility:
FEMALE
Brief Summary
The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).
Detailed Description
Preeclampsia affects about 3-5% of all pregnancies and is estimated to cause at least 42 000 maternal deaths annually, remaining an important cause of death and complications for the mother and baby. ...
Eligibility Criteria
Inclusion
- singleton pregnant women
- with a history of two or more miscarriages
Exclusion
- indication to a treatment according to the severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease, malignancy,
- major malformation of the fetus diagnosed at 11-13 weeks of gestation.
- Known paternal, maternal, or embryo chromosome abnormality;
- Abnormal uterine anatomy at hysterosalpingography/hysteroscopy or hydrosonography that might explain RM in the first trimester of pregnancy;
- Maternal endocrine dysfunction: premature ovarian failure, hyperprolactinemia, corpus luteal insufficiency, untreated diabetes mellitus or untreated thyroid dysfunction.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
462 Patients enrolled
Trial Details
Trial ID
NCT06020378
Start Date
January 1 2024
End Date
December 1 2026
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Jiao Tong University School of Medicine，Renji Hospital
Shanghai, Shanghai Municipality, China, 200127